Any current/future new fundraising through debt or equity?

No explicit mention of any new fundraising through debt or equity in the current call transcript. Gross debt as of March 31, 2026, stands at INR 2,295 crore with a net debt of INR 1,911 crore. Moratorium of 2 years on existing debt is mentioned, implying no immediate pressure to raise new debt. Focus emphasized on disciplined debt management and working capital investments to reduce net debt-to-EBITDA below 1.0x by FY29. Capex guidance for FY27 and FY28 is maintenance level (~INR 25 crore annually), indicating no large capital requirement triggering potential fundraising. No announcement on ne

Any current/future capex/capital investment/strategic investment?

The company has invested around INR 59 crore in expanding capacity at Prag distillery in Andhra Pradesh, increasing capacity from 6 lakh to 36 lakh cases per annum; this expansion is complete and operational. Maintenance capex for FY27 and FY28 is estimated at approximately INR 25 crore per year, indicating no large capital expenditure planned. There is an investment plan of up to INR 30 crore in the Nigerian subsidiary to support an existing business of around 2.5 lakh cases. Investment in recommissioning the Shrirampur ENA distillery is under consideration, with no set timeline yet. No furth

Future growth expectations in sales/revenue/volumes?

FY27: Expected high-single digit to low-double digit volume growth for the combined business. Next couple of years: Anticipated double-digit volume growth. Next 3 years: Projected double-digit volume CAGR. Imperial Blue business: Expected to exceed the volume and revenue levels of FY25 acquisition base by FY27. Brand expansion ongoing in new geographies starting FY27, including launching brandy in northern markets. Revenue growth guidance shaped by price adjustments and market expansions, despite changes in accounting for selling expenses. Margins to improve alongside volume growth

Future growth expectations in earnings/operating earnings/profits/EPS?

FY27 volume growth expected at high-single digit to low-double digit, with a double-digit CAGR over the next 3 years. Consolidated EBITDA margins anticipated to reach 16%-18% within 24-36 months. Margin expansion guidance includes benefits from cost optimizations, operating leverage, price increases, and India-UK FTA custom duty reductions. Net debt-to-EBITDA ratio targeted to fall below 1.0x by FY29, indicating disciplined debt management. Staff costs expected to stabilize at current run rates, supporting operational efficiency. Revenue recognition changes will improve EBITDA and PAT margins

IN US

Sale is live|00:00:00left today

Tilaknagar Industries LtdQ1 FY26Beverages

Tilaknagar Industries Ltd Q1 FY26 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹436P/E: 40.6Market Cap: ₹11.5K CrSector: Beverages

Management growth scorecard

Revenue

Category 3

Margin

Category 1

Fundraise

N/A

Order

N/A

Capex

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

→FY27: Expected high-single digit to low-double digit volume growth for the combined business.
→Next couple of years: Anticipated double-digit volume growth.
→Next 3 years: Projected double-digit volume CAGR.
→Imperial Blue business: Expected to exceed the volume and revenue levels of FY25 acquisition base by FY27.
→Brand expansion ongoing in new geographies starting FY27, including launching brandy in northern markets.
→Revenue growth guidance shaped by price adjustments and market expansions, despite changes in accounting for selling expenses.
→Margins to improve alongside volume growth with targeted EBITDA margin of 16%-18% over 24-36 months.
→Policy changes like MRP reductions in Karnataka expected to drive further volume uptake.

Margin guidance

Category 1

→FY27 volume growth expected at high-single digit to low-double digit, with a double-digit CAGR over the next 3 years.
→Consolidated EBITDA margins anticipated to reach 16%-18% within 24-36 months.
→Margin expansion guidance includes benefits from cost optimizations, operating leverage, price increases, and India-UK FTA custom duty reductions.
→Net debt-to-EBITDA ratio targeted to fall below 1.0x by FY29, indicating disciplined debt management.
→Staff costs expected to stabilize at current run rates, supporting operational efficiency.
→Revenue recognition changes will improve EBITDA and PAT margins without affecting absolute profits.
→Deferred consideration of EUR 28 million to be paid post 4 years of Imperial Blue acquisition; no further major acquisition-related costs expected.
→New product development and luxury segment focus through Spaceman Spirits Lab expected to drive future earnings growth.

3 more insights locked — sign up free to unlock

Fundraise plans

→No explicit mention of any new fundraising through debt or equity in the current call transcript.
→Gross debt as of March 31, 2026, stands at INR 2,295 crore with a net debt of INR 1,911 crore.
→Moratorium of 2 years on existing debt is mentioned, implying no immediate pressure to raise new debt.
→Focus emphasized on disciplined debt management and working capital investments to reduce net debt-to-EBITDA below 1.0x by FY29.
→Capex guidance for FY27 and FY28 is maintenance level (~INR 25 crore annually), indicating no large capital requirement triggering potential fundraising.
→No announcement on new equity issuance or plans to raise capital via equity.
→Management's closing remarks focus on growth and operational excellence, without flagging any fundraising plans.

Order book

The transcript provided on page 15 and surrounding pages does not mention any information related to current or expected orderbook or pending orders. The discussion primarily revolves around: - Financial results and performance (Q4 & FY26). - Transition and integration of Imperial Blue business. - TSMA fees and operational cost structuring. - Growth outlook including volume and margin guidance. - Supply chain expansions and cost optimizations. - Market developments and regional impacts on business. - No reference to orderbook or pending orders is found in the transcript. Therefore, there is no information available on current or expected orderbook or pending orders in the provided document.

Capex plans

→The company has invested around INR 59 crore in expanding capacity at Prag distillery in Andhra Pradesh, increasing capacity from 6 lakh to 36 lakh cases per annum; this expansion is complete and operational.
→Maintenance capex for FY27 and FY28 is estimated at approximately INR 25 crore per year, indicating no large capital expenditure planned.
→There is an investment plan of up to INR 30 crore in the Nigerian subsidiary to support an existing business of around 2.5 lakh cases.
→Investment in recommissioning the Shrirampur ENA distillery is under consideration, with no set timeline yet.
→No further significant investments or new launches were explicitly disclosed, though new product development (NPD) pipeline and luxury/premium launches are in progress without detailed timelines.

How does Tilaknagar Industries Ltd rank vs peers in Beverages?

Pro feature

1Tilaknagar Industries Ltd

Rev 3Mar 1

See full Beverages sector rankings

Want more stocks like Tilaknagar Industries Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio